Literature DB >> 2302519

Intragastric balloons for morbid obesity: results, patient tolerance and balloon life span.

E M Mathus-Vliegen1, G N Tytgat.   

Abstract

Sixty morbidly obese patients were treated with 88 intragastric balloons. An air-filled intragastric balloon was used, which was permanently connected to an inflation catheter exiting through the nose. Patients were evaluated for loss of body weight and tolerance of the balloon; the balloon was inspected for efficacy and safety. A mean total loss of body weight of 21 kg was obtained after a mean of 39 weeks in 15 men (mean age 37.7 years) and 45 women (mean age 36.2 years), with a mean initial weight of 127.9 kg. The maximum rate of weight loss occurred in the first 6 months, with a steady decrease of 1 kg per week; thereafter the rate declined. Subjective complaints were infrequent and consisted of nasal discomfort or abdominal symptoms. Intolerance in 12 per cent of patients was due to enhanced hunger (one patient), nasal pulling sensation (four patients) and symptomatic ulcer (two patients). Fifteen patients asked for removal of the well functioning balloon after a mean of 169 days; 14 of the 15 balloons were still airtight. Forty balloons failed prematurely. Nine were retrieved orally and 31 were passed per anum, of which 28 passed with mild abdominal cramping, two patients required transabdominal puncture and one needed laparotomy. Even the 40 prematurely removed balloons remained in situ for a mean of 108 days; only one-third showed leakage. As yet, 33 well functioning balloons have been in situ for a mean of 167 days. Well functioning balloons deflated at a rate of 2.3 ml per day. Malfunctioning of the balloon was due to leakage in 12 cases and to clogging of the inflation catheter in three cases. Major complications (8 per cent) included two gastric ulcers and three cases of mild ileus. One ileus patient required surgery (2 per cent). The reported intragastric balloon model is effective and safe. We recommended this type of balloon as a weight reducing adjuvant therapy before bariatric surgery.

Entities:  

Mesh:

Year:  1990        PMID: 2302519     DOI: 10.1002/bjs.1800770127

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  16 in total

1.  Large bowel impaction by the BioEnterics Intragastric Balloon (BIB) necessitating surgical intervention.

Authors:  W Y Kim; U J Kirkpatrick; A P Moody; P N Wake
Journal:  Ann R Coll Surg Engl       Date:  2000-05       Impact factor: 1.891

Review 2.  Retention of nondeflating balloon in small bowel. Case report and review of the literature.

Authors:  A V Thillainayagam; J A Dias; F Mourad; C B Williams; R Reznek; M J Farthing
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

3.  Air-filled vs water-filled intragastric balloon: a prospective randomized study.

Authors:  Cristiano Giardiello; Alessandro Borrelli; Eufemia Silvestri; Valentina Antognozzi; Giuseppe Iodice; Michele Lorenzo
Journal:  Obes Surg       Date:  2012-12       Impact factor: 4.129

Review 4.  Intragastric Balloon for Management of Severe Obesity: a Systematic Review.

Authors:  Ekua Yorke; Noah Jacob Switzer; Artan Reso; Xinhe Shi; Christopher de Gara; Daniel Birch; Richdeep Gill; Shahzeer Karmali
Journal:  Obes Surg       Date:  2016-09       Impact factor: 4.129

5.  Efficacy, safety, and tolerance of two types of intragastric balloons placed in obese subjects: a double-blind comparative study.

Authors:  Maria Luisa De Castro; María José Morales; Víctor Del Campo; Juan R Pineda; Eduardo Pena; José M Sierra; María José Arbones; Ignacio R Prada
Journal:  Obes Surg       Date:  2010-12       Impact factor: 4.129

6.  Mechanical ileus induces surgical intervention due to gastric balloon: a case report and review of the literature.

Authors:  Marty Zdichavsky; Stefan Beckert; Markus Kueper; Michael Kramer; Alfred Königsrainer
Journal:  Obes Surg       Date:  2010-12       Impact factor: 4.129

7.  Obesity surgery: evidence-based guidelines of the European Association for Endoscopic Surgery (EAES).

Authors:  S Sauerland; L Angrisani; M Belachew; J M Chevallier; F Favretti; N Finer; A Fingerhut; M Garcia Caballero; J A Guisado Macias; R Mittermair; M Morino; S Msika; F Rubino; R Tacchino; R Weiner; E A M Neugebauer
Journal:  Surg Endosc       Date:  2004-12-02       Impact factor: 4.584

8.  Six months of balloon treatment does not predict the success of gastric banding.

Authors:  Suzan de Goederen-van der Meij; Robert G J M Pierik; Marco Oudkerk Pool; Dirk J Gouma; Lisbeth M Mathus-Vliegen
Journal:  Obes Surg       Date:  2007-01       Impact factor: 4.129

9.  Safety of the Ullorex oral intragastric balloon for the treatment of obesity.

Authors:  Corby K Martin; Drake E Bellanger; Kristina K Rau; Sandra Coulon; Frank L Greenway
Journal:  J Diabetes Sci Technol       Date:  2007-07

10.  Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity.

Authors:  Maria Asuncion Martinez-Brocca; Ovidio Belda; Juana Parejo; Luis Jimenez; Agustin del Valle; Jose Luis Pereira; Felipe Garcia-Pesquera; Ricardo Astorga; Alfonso Leal-Cerro; Pedro Pablo Garcia-Luna
Journal:  Obes Surg       Date:  2007-05       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.